Evidence mapPaperPMID 37188259Full record

ArticleFrontiers in health services2023

Designing implementation strategies to improve identification, cascade testing, and management of families with familial hypercholesterolemia: An intervention mapping approach.

Laney K Jones, Evan M Calvo, Gemme Campbell-Salome, Nicole L Walters, Andrew Brangan, Gabriela Rodriguez, Catherine D Ahmed, Kelly M Morgan, Samuel S Gidding, Marc S Williams and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Frontiers in health services, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Laney K JonesDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Evan M CalvoDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Gemme Campbell-SalomeDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Nicole L WaltersDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Andrew BranganDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Gabriela RodriguezDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Catherine D AhmedFamily Heart Foundation, Pasadena, CA, United States.
Kelly M MorganDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Samuel S GiddingDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Marc S WilliamsDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Ross C BrownsonPrevention Research Center in St. Louis, Brown School, Washington University in St. Louis, St. Louis, MO, United States.
Terry L SeatonUniversity of Health Sciences and Pharmacy in St. Louis, St. Louis, MO, United States.
Anne C GoldbergDivision of Endocrinology, Metabolism and Lipid Research, John T. Milliken Department of Internal Medicine, Washington University School of Medicine in St. Louis, Washington University in St. Louis, St. Louis, MO, United States.
Mary P McGowanFamily Heart Foundation, Pasadena, CA, United States.
Alanna K RahmDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Amy C SturmDepartment of Genomic Health, Research Institute, Geisinger, Danville, PA, United States.
Genomic Health (United States) · USGeisinger Health System · USHeart Foundation · USWashington University in St. Louis · USCommonwealth Medical College · USUniversity of Health Sciences and Pharmacy · US

Funding

Identification Methods, Patient Activation, and Cascade Testing for FH: IMPACT-FHR01HL148246 · NHLBI · GEISINGER CLINIC · PI Ana Morales Reyes · 2019 to 2026
$5.1M
Washington University K12 Program in T4 Implementation ResearchK12HL137942 · NHLBI · WASHINGTON UNIVERSITY · PI DAVILA-ROMAN, VICTOR G. · 2017 to 2021
$3.1M
Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia: CARE-FHR61HL161775 · NHLBI · GEISINGER CLINIC · PI GIDDING, SAMUEL S, JONES, LANEY K · 2022 to 2022
$423k
NHLBI NIH HHS K12 HL137942NHLBI NIH HHS R01 HL148246NHLBI NIH HHS R61 HL161775
6 · The paper itself

Abstract

Introduction: Familial hypercholesterolemia (FH) is a common inherited cholesterol disorder that, without early intervention, leads to premature cardiovascular disease. Multilevel strategies that target all components of FH care including identification, cascade testing, and management are needed to address gaps that exist in FH care. We utilized intervention mapping, a systematic implementation science approach, to identify and match strategies to existing barriers and develop programs to improve FH care. Methods: Data were collected utilizing two methods: a scoping review of published literature, related to any component of FH care, and a parallel mixed method study using interviews and surveys. The scientific literature was searched using key words including "barriers" or "facilitators" and "familial hypercholesterolemia" from inception to December 1, 2021. The parallel mixed method study recruited individuals and families with FH to participate in either dyadic interviews ( Results: In steps 1-3, a needs assessment found barriers to FH care included underdiagnosis of the condition which led to suboptimal management due to a myriad of determinants including knowledge gaps, negative attitudes, and risk misperceptions by individuals with FH and clinicians. Literature review highlighted barriers to FH care at the health system level, notably the relative lack of genetic testing resources and infrastructure needed to support FH diagnosis and treatment. Examples of strategies to overcome identified barriers included development of multidisciplinary care teams and educational programs. In steps 4-6, an NHLBI-funded study, the Collaborative Approach to Reach Everyone with FH (CARE-FH), deployed strategies that focused on improving identification of FH in primary care settings. The CARE-FH study is used as an example to describe program development, implementation, and evaluation techniques of implementation strategies. Conclusion: The development and deployment of evidence-based implementation strategies that address barriers to FH care are important next steps to improve identification, cascade testing, and management.

Indexed as

cascade testingcholesterolfamilial hypercholesterolemiaidentificationimplementation scienceintervention mappingmanagementtreatment

Identifiers

PMID37188259
PMCPMC10175779
OpenAlexW4367320298

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.